Research Index entry · Trial
PRI-002, a pill aimed at toxic amyloid clumps, missed its main goal
- Evidence
- People · mid-stage trial
- Source
- clinicaltrials.gov
- Added
- 2 October 2026
What it is
PRI-002 is a daily pill from Priavoid designed to break up small toxic clumps of amyloid. In the PRImus-AD trial of 304 people, it didn’t slow decline more than a placebo at 48 weeks.
Where it stands
- Lab discovery
- Animal studies
- First studies in people
- Large trials
- Approved
A miss in a mid-stage trial. Priavoid will show the full data at meetings in 2027.
Update timeline
What changed
Newest first. Only changes to the subject itself appear here: new information, or something proven wrong.
- WatchingThe Scouts look again every Friday
Only new information or a correction shows up here, not another mention of the same thing.
- Update
Research connections
Why these belong together
A connection has to say what it adds. Shared keywords alone don’t count.
Trial · Trial registry
AR1001 missed its main goal in its final-stage trialThe other pill that reported at the same research meeting, in November 2026.
People · final-stage trial · company data